Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$879.62 USD

879.62
835,307

-5.93 (-0.67%)

Updated Oct 4, 2024 12:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.

Has Alimera Sciences (ALIM) Outpaced Other Medical Stocks This Year?

Here is how Alimera Sciences (ALIM) and Eli Lilly (LLY) have performed compared to their sector so far this year.

AstraZeneca (AZN) Beats on Q2 Earnings, Ups Sales Growth View

AstraZeneca's (AZN) second-quarter results reflect a beat on both counts (revenues and earnings). AZN raises its 2022 sales growth guidance, keeping its profit forecast unchanged.

AbbVie (ABBV) Q2 Earnings Beat Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 1.81% and 0.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

Eli Lilly (LLY) closed at $330.80 in the latest trading session, marking a +0.57% move from the prior day.

Sanofi (SNY) Q2 Earnings & Sales Beat, Ups 2022 Growth View

Sanofi (SNY) beats second-quarter estimates for earnings and sales. Dupixent drives sales growth and a strong recovery in travel vaccines. The company raises its earnings growth guidance for 2022.

Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to Decline

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (MRK) Surpasses Q2 Earnings and Revenue Estimates

Merck (MRK) delivered earnings and revenue surprises of 11.98% and 5.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Innoviva (INVA) Misses Q2 Earnings Estimates

Innoviva (INVA) delivered earnings and revenue surprises of -90.91% and 4.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

TEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B

TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact. The company agrees to settle opioid lawsuits for as much as $4.25 billion.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $328.75, marking a +0.56% move from the previous day.

Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $326.92, marking a +1.52% move from the previous day.

Sweta Killa headshot

Healthcare ETFs in Focus Ahead of Q2 Earnings

The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.

The Zacks Analyst Blog Highlights Eli Lilly, Thermo Fisher Scientific, TotalEnergies, Amgen and Marathon Petroleum

Eli Lilly, Thermo Fisher Scientific, TotalEnergies, Amgen and Marathon Petroleum have been included in this Analyst Blog.

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

Eli Lilly (LLY) closed at $331.60 in the latest trading session, marking a +1.44% move from the prior day.

Sheraz Mian headshot

Top Stock Reports for Eli Lilly, Thermo Fisher & TotalEnergies

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Thermo Fisher Scientific Inc. (TMO), and TotalEnergies SE (TTE).

Strength Seen in H Lundbeck AS (HLUYY): Can Its 11.2% Jump Turn into More Strength?

H Lundbeck AS (HLUYY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

Eli Lilly (LLY) closed at $331.07 in the latest trading session, marking a +0.18% move from the prior day.

Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?

Incyte (INCY) outperforms the industry in the year so far as lead drug Jakafi maintains momentum. Pipeline progress has also been encouraging.

Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study

Radius (RDUS) randomizes the first patient in the SCOUT-015 study of pipeline candidate, RAD011, for Prader-Willi Syndrome.

Biogen (BIIB) Lecanemab Gets FDA Priority Tag for Alzheimer's

The FDA sets a target date of Jan 6, 2023 for Biogen (BIIB) and partner Eisai's regulatory filing, which seeks accelerated approval for lecanemab to treat Alzheimer's disease (AD).

Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

Eli Lilly (LLY) closed the most recent trading day at $327.18, moving +0.76% from the previous trading session.